Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Phosphodiesterases and cAMP Pathway in Pituitary Diseases.

Bizzi MF, Bolger GB, Korbonits M, Ribeiro-Oliveira A Jr.

Front Endocrinol (Lausanne). 2019 Mar 19;10:141. doi: 10.3389/fendo.2019.00141. eCollection 2019. Review.

2.

Reduced protein expression of the phosphodiesterases PDE4A4 and PDE4A8 in AIP mutation positive somatotroph adenomas.

Bizzi MF, Pinheiro SVB, Bolger GB, Schweizer JROL, Giannetti AV, Dang MN, Ribeiro-Oliveira A Jr, Korbonits M.

Mol Cell Endocrinol. 2018 Nov 15;476:103-109. doi: 10.1016/j.mce.2018.04.014. Epub 2018 May 3.

3.

Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus.

Campbell SL, van Groen T, Kadish I, Smoot LHM, Bolger GB.

BMC Neurosci. 2017 Dec 2;18(1):77. doi: 10.1186/s12868-017-0396-6.

4.

The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.

Bolger GB.

Adv Neurobiol. 2017;17:63-102. doi: 10.1007/978-3-319-58811-7_4. Review.

PMID:
28956330
5.

The RNA-binding protein SERBP1 interacts selectively with the signaling protein RACK1.

Bolger GB.

Cell Signal. 2017 Jul;35:256-263. doi: 10.1016/j.cellsig.2017.03.001. Epub 2017 Mar 4.

6.

cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.

Bolger GB, Bizzi MF, Pinheiro SV, Trivellin G, Smoot L, Accavitti MA, Korbonits M, Ribeiro-Oliveira A Jr.

Endocr Relat Cancer. 2016 May;23(5):419-31. doi: 10.1530/ERC-15-0205.

7.

RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.

Bolger GB.

Cell Signal. 2016 Jul;28(7):706-12. doi: 10.1016/j.cellsig.2015.08.003. Epub 2015 Aug 6.

8.

Testicular Cancer, Version 2.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R.

J Natl Compr Canc Netw. 2015 Jun;13(6):772-99.

PMID:
26085393
9.

Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder.

Paluri RK, Morgan CJ, Mooney DJ, Mgbemena O, Yang ES, Wei S, Kouba E, Naik G, El Mouallem NR, Poston T, Jones B, Nix J, Bolger GB, Deshazo M, Sonpavde G.

Clin Genitourin Cancer. 2015 Oct;13(5):469-75. doi: 10.1016/j.clgc.2015.02.010. Epub 2015 Mar 6.

PMID:
25868964
10.

Kidney cancer, version 3.2015.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Feb;13(2):151-9.

PMID:
25691606
11.

Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.

Bolger GB, Dunlop AJ, Meng D, Day JP, Klussmann E, Baillie GS, Adams DR, Houslay MD.

Cell Signal. 2015 Apr;27(4):756-69. doi: 10.1016/j.cellsig.2014.12.009. Epub 2014 Dec 27.

12.

Kidney cancer, version 2.2014.

Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R; Natiomal compresensive cancer networks.

J Natl Compr Canc Netw. 2014 Feb;12(2):175-82.

PMID:
24586079
13.

Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.

Lambert JA, Raju SV, Tang LP, McNicholas CM, Li Y, Courville CA, Farris RF, Coricor GE, Smoot LH, Mazur MM, Dransfield MT, Bolger GB, Rowe SM.

Am J Respir Cell Mol Biol. 2014 Mar;50(3):549-58. doi: 10.1165/rcmb.2013-0228OC.

14.

Testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. No abstract available.

PMID:
22491049
15.

Kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Nov 1;9(11):xlv.

PMID:
21917622
16.

Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators.

Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, Rowe SM.

Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L587-97. doi: 10.1152/ajplung.00465.2010. Epub 2011 Jul 1.

17.

Interaction between LIS1 and PDE4, and its role in cytoplasmic dynein function.

Murdoch H, Vadrevu S, Prinz A, Dunlop AJ, Klussmann E, Bolger GB, Norman JC, Houslay MD.

J Cell Sci. 2011 Jul 1;124(Pt 13):2253-66. doi: 10.1242/jcs.082982. Epub 2011 Jun 7.

18.

A phase II trial of weekly i.v. KW-2170 in advanced castrate-resistant prostate cancer.

De Souza PL, North S, Bolger GB, Spiridonidis H, Lim R, Khoo KS, Phillips J, Fujimori M.

Asia Pac J Clin Oncol. 2010 Dec;6(4):292-7. doi: 10.1111/j.1743-7563.2010.01328.x. Epub 2010 Nov 3.

PMID:
21114779
19.

Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.

Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K, Stals K, Khoo B, Kumar AV, Ellard S, Grossman AB, Korbonits M; International FIPA Consortium.

Hum Mutat. 2010 Aug;31(8):950-60. doi: 10.1002/humu.21292.

20.

NCCN clinical practice guidelines in oncology: kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. No abstract available.

PMID:
19555584
21.

NCCN clinical practice guidelines in oncology: testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. No abstract available.

PMID:
19555582
22.

The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.

Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M.

J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401. doi: 10.1210/jc.2007-2611. Epub 2008 Apr 1.

PMID:
18381572
23.

Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Mackenzie KF, Topping EC, Bugaj-Gaweda B, Deng C, Cheung YF, Olsen AE, Stockard CR, High Mitchell L, Baillie GS, Grizzle WE, De Vivo M, Houslay MD, Wang D, Bolger GB.

Biochem J. 2008 Apr 15;411(2):361-9.

24.

1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.

Smith KJ, Baillie GS, Hyde EI, Li X, Houslay TM, McCahill A, Dunlop AJ, Bolger GB, Klussmann E, Adams DR, Houslay MD.

Cell Signal. 2007 Dec;19(12):2612-24. Epub 2007 Sep 1.

PMID:
17900862
25.

Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels.

Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, Houslay MD.

J Neurosci. 2007 Aug 29;27(35):9513-24.

26.

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.

Baillie GS, Adams DR, Bhari N, Houslay TM, Vadrevu S, Meng D, Li X, Dunlop A, Milligan G, Bolger GB, Klussmann E, Houslay MD.

Biochem J. 2007 May 15;404(1):71-80.

27.

Kidney cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. No abstract available.

PMID:
17112454
28.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
29.

Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.

Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, Mitchell LH, McCahill A, Hundsrucker C, Klussmann E, Adams DR, Houslay MD.

Biochem J. 2006 Aug 15;398(1):23-36.

30.
31.

Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.

Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ.

Prostate. 2005 Dec 1;65(4):316-21.

PMID:
16015596
32.

The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins.

Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, Houslay MD.

J Biol Chem. 2003 Dec 5;278(49):49230-8. Epub 2003 Sep 18.

33.

Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.

Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD.

J Biol Chem. 2003 Aug 29;278(35):33351-63. Epub 2003 Jun 16.

34.

Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.

Shepherd M, McSorley T, Olsen AE, Johnston LA, Thomson NC, Baillie GS, Houslay MD, Bolger GB.

Biochem J. 2003 Mar 1;370(Pt 2):429-38.

35.

The RACK1 scaffold protein: a dynamic cog in cell response mechanisms.

McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ.

Mol Pharmacol. 2002 Dec;62(6):1261-73. Review. No abstract available.

PMID:
12435793
36.

Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.

Bolger GB, McCahill A, Yarwood SJ, Steele MR, Warwicker J, Houslay MD.

BMC Biochem. 2002 Aug 23;3:24.

37.

Identification of a surface on the beta-propeller protein RACK1 that interacts with the cAMP-specific phosphodiesterase PDE4D5.

Steele MR, McCahill A, Thompson DS, MacKenzie C, Isaacs NW, Houslay MD, Bolger GB.

Cell Signal. 2001 Jul;13(7):507-13.

PMID:
11516626
38.

Surgically induced cryptorchidism-related degenerative changes in spermatogonia are associated with loss of cyclic adenosine monophosphate-dependent phosphodiesterases type 4 in abdominal testes of rats.

Farooqui SM, Al-Bagdadi F, Houslay MD, Bolger GB, Stout R, Specian RD, Cherry JA, Conti M, O'Donnell JM.

Biol Reprod. 2001 Jun;64(6):1583-9.

PMID:
11369582
40.

UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.

Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB.

J Biol Chem. 2000 Apr 7;275(14):10349-58.

41.
42.

The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains.

Beard MB, O'Connell JC, Bolger GB, Houslay MD.

FEBS Lett. 1999 Oct 22;460(1):173-7.

43.

The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform.

Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB.

J Biol Chem. 1999 May 21;274(21):14909-17. Erratum in: J Biol Chem 2001 Mar 2;276(9):6879.

44.

Molecular genetic approaches. I. Two-hybrid systems.

Bolger GB.

Methods Mol Biol. 1998;88:101-31. No abstract available.

PMID:
9664301
45.
47.

Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, Houslay MD.

Biochem J. 1997 Dec 1;328 ( Pt 2):549-58.

48.

Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD.

Biochem J. 1997 Dec 1;328 ( Pt 2):539-48.

50.

Supplemental Content

Loading ...
Support Center